UP421

Phase 1Biologic

PPer-Ola Carlsson

UP421 is one of 20 biologic programs targeting Type 1 Diabetes. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 DiabetesActive, not recruiting

Type 1 DiabetesPhase 1

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Symlin

AstraZeneca

Preclinical

3 2

Aldomet

Neurocrine Biosciences

Preclinical

2 3

Glargine

Eli Lilly

Preclinical

4 4

Pitocin

RRetrophin

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 7

Foradil

Viatris

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Teplizumab

Sanofi

Preclinical

8 10

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes1 trial

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

Recruiting·PPer-Ola Carlsson·Phase 1·NCT06239636·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for UP421. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UP421 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UP421. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Per-Ola Carlsson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: PPer-Ola Carlsson

UP421

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes1 trial

References

Drug Info

Quick Facts

Related News